Startups set off new wave of mRNA therapeutics
Elie Dolgin • September 2, 2021
After the vaccine triumphs of Pfizer/BioNTech and Moderna, a raft of startups is developing mRNA, circular RNA and self-amplifying RNA therapeutics.
A cadre of new startups are building next-generation RNA platform technologies designed to solve some of the unique challenges associated with using conventional mRNA tools as therapeutics.
Read more at Nature Biotechnology.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.